Donidalorsen trials showed positive results in treating patients with hereditary angioedema, exhibiting significant reductions in attack rates, according to a study published in The New England Journal of Medicine.
The study findings support the potential prophylactic use of the drug for HAE, with patients reporting significant and clinically meaningful improvements in their quality of life and disease control, Marc A. Riedl, MD, clinical director, U.S. HAEA Angioedema Center, University of California at San Diego, and colleagues wrote.
“People living with HAE can experience significant